response rates to combination chemotherapy , including cisplatin + doxorubicin , cisplatin + cyclophosphamide , and cisplatin + doxorubicin + cyclophosphamide , have ranged from 12 % to 78 % .
C0279212
cisplatin
C0013089
doxorubicin